[Federal Register Volume 62, Number 130 (Tuesday, July 8, 1997)]
[Notices]
[Pages 36528-36533]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-17699]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Announcement 773]
National Organizational Strategies for the Prevention, Early
Detection, and Control of Cancers
Introduction
The Centers for Disease Control and Prevention (CDC) announces the
availability of funds for fiscal year (FY)1997 for competing
cooperative agreements to conduct nationwide educational activities
related to the delivery of prevention, early detection, and control of
cancers, especially cancers of the breast, cervix, colon, rectum, and
skin for priority populations (including, but not limited to Hispanics,
African-Americans, American Indian/Alaska Natives, older Americans,
urban Americans, youths, etc.).
CDC is committed to achieving the health promotion and disease
prevention objectives of Healthy People 2000, a national activity to
reduce morbidity and mortality and to improve the quality of life. This
announcement is related to the priority areas of Cancer. (To order a
copy of Healthy People 2000, see the section ``Where To Obtain
Additional Information'.)
Authority
This program is authorized by Sections 317(k)(2) [42 U.S.C.
247b(k)(2)] of the Public Health Service Act, as amended.
Smoke-Free Workplace
CDC strongly encourages all grant recipients to provide a smoke-
free workplace and to promote the nonuse of all tobacco products, and
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities that receive Federal funds in which education,
library, day care, health care, or early childhood development services
are provided to children.
Eligible Applicants
Eligible applicants are private and public nonprofit national
organizations that have established and conducted nationwide programs
and activities related to health promotion and disease prevention.
National organizations and their regional, State, and local
constituents provide a unique opportunity to develop and conduct
interventions to address barriers to prevention and screening, improve
the quality of care, and improve the priority population's access to
cancer prevention and early detection programs. National organizations
that have established credible working relationships with priority
populations or which can impact these populations through policy or
resource allocation can identify appropriate recruitment strategies,
interpersonal channels, education messages, resources and
organizational linkages, learning modules, and instructional tools that
will assist increasing participation in cancer prevention and early
detection programs nationwide.
All private, nonprofit organizations must include evidence of its
nonprofit status with the application. Any of the following is
acceptable evidence.
(a) A reference to the organization's listing in the Internal
Revenue Service's (IRS) most recent list of tax-exempt organizations
described in section 501(c)(3) of the IRS Code.
(b) A copy of a currently valid Internal Revenue Service Tax
exemption certificate.
(c) A statement from a State taxing body, State Attorney General,
or other appropriate State official certifying that the applicant
organization has a nonprofit status and that none of the net earnings
accrue to any private shareholders or individuals.
(d) A certified copy of the organization's certificate of
[[Page 36529]]
incorporation or similar document if it clearly establishes the
nonprofit status of the organization.
Note: Effective January 1, 1996, Public Law 104-65 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code of 1986 which engages in lobbying activities will not
be eligible for the receipt of Federal funds constituting an award,
grant, cooperative agreement, contract, loan, or any other form.
Availability of Funds
Approximately $1 million is available in FY 1997 for approximately
6 awards. It is expected that the average award will be $150,000,
ranging from $100,000 to $200,000. It is expected that the awards will
begin on or about September 30, 1997, and will be made for a 12-month
budget period within a project period of up to 5 years. It is expected
that CDC will fund approximately 3 projects for breast and cervical
cancer; approximately 1 project for colorectal cancer; approximately 1
project for skin cancer and approximately 1 project for a cross-cutting
activity which may impact more than one priority cancer. Funding
estimates may vary and are subject to change.
Continuation awards within the approved project period will be made
on the basis of satisfactory progress and the availability of funds.
Funds may not be expended for the purchase or lease of land or
buildings, construction of facilities, renovation of existing space, or
the delivery of clinical and therapeutic services. The purchase of
equipment is discouraged but will be considered for approval if
justified on the basis of being essential to the program and not
available from any other source.
Use of Funds
Restrictions on Lobbying
Applicants should be aware of restrictions on the use of Department
of Health and Human Services (HHS) funds for lobbying of Federal or
State legislative bodies. Under the provisions of 31 U.S.C. Section
1352 (which has been in effect since December 23, 1989), recipients
(and their subtier contractors) are prohibited from using appropriated
Federal funds (other than profits from a Federal contract) for lobbying
Congress or any Federal agency in connection with the award of a
particular contract, grant, cooperative agreement, or loan. This
includes grants/cooperative agreements that, in whole or in part,
involve conferences for which Federal funds cannot be used directly or
indirectly to encourage participants to lobby or to instruct
participants on how to lobby.
In addition, the FY 1997 Departments of Labor, HHS, and Education,
and Related Agencies Appropriations Act, which became effective October
1, 1996 expressly prohibits the use of 1997 appropriated funds for
indirect or ``grass roots'' lobbying efforts that are designed to
support or defeat legislation pending before State legislatures.
Section 503 of this new law, as enacted by the Omnibus Consolidated
Appropriations Act, 1997, Division A, Title I, Section 101(e), Pub. L.
No. 104-208 (September 30, 1996), provides as follows:
Sec. 503(a) No part of any appropriation contained in this Act
shall be used, other than for normal and recognized executive-
legislative relationships, for publicity or propaganda purposes, for
the preparation, distribution, or use of any kit, pamphlet, booklet,
publication, radio, television, or video presentation designed to
support or defeat legislation pending before the Congress, * * * except
in presentation to the Congress or any State legislative body itself.
(b) No part of any appropriation contained in this Act shall be
used to pay the salary or expenses of any grant or contract recipient,
or agent acting for such recipient, related to any activity designed to
influence legislation or appropriations pending before the Congress or
any State legislature.
Background
One of every five deaths in the United States is of cancer. The
American Cancer Society (ACS) estimates that approximately 7.4 million
Americans alive today have a history of cancer. In the last half-
century, the cancer mortality rate in the United States has risen
steadily. The age-adjusted rate in 1930 was 143 per 100,000 population.
It rose to 158 in 1950, to 163 in 1970, and to 174 in 1990. In 1997,
about 560,000 people will die of cancer--over 1,500 people a day.
In 1997, about 1,382,400 new cancer cases will be diagnosed. This
estimate does not include carcinoma in situ and basal and squamous cell
skin cancers. The incidence of these skin cancers is estimated to be
more than 900,000 cases annually.
The financial costs of the disease are significant. Cancer accounts
for about 10 percent of the total cost of disease in the United States.
The National Cancer Institute (NCI) estimates overall costs for cancer
at $104 billion; $35 billion for direct medical costs, $12 billion for
morbidity costs (cost of lost productivity), and $57 billion for
mortality costs.
CDC's Division of Cancer Prevention and Control (DCPC), within the
National Center for Chronic Disease Prevention and Health Promotion,
provides technical consultation, assistance, and training to State and
local public health departments and other health care provider
organizations to improve education, training, and skills in the
prevention, detection, and control of selected cancers, including
breast, cervical, colorectal, and skin cancers. In its commitment to
reach the targeted populations at risk for developing cancer, the
division encourages States to build local coalitions and to implement
relevant grassroots and community activities.
Breast Cancer
Among women, breast cancer is the second leading cause of cancer-
related deaths. An estimated one of every eight women in the United
States will develop breast cancer in her lifetime. In 1997, the
American Cancer Society estimates that 180,200 women will be diagnosed
with invasive breast cancer and 43,900 women will die of this disease.
According to the most recent data, mortality rates are decreasing among
white women, but not among African-American women.
The percent of women screened for breast cancer decreases with age.
Approximately 70 percent of women aged 50 years and older reported in
the 1995 Behavioral Risk Factor Surveillance System (BRFSS) having had
a mammogram within the last two years. This proportion was much lower
for racial and ethnic minority women, for women who had less than a
high school education, for women who were over age 75 years, and for
women who were living below the poverty level. In Healthy People 2000,
the Public Health Service (PHS) established that by the year 2000, 60
percent of all women aged 50 years and older should receive a mammogram
every 2 years.
Cervical Cancer
The overall incidence of invasive cervical cancer has decreased
steadily over the last several decades, but in recent years, this rate
has increased among women who are younger than 50 years. In 1997,
invasive cervical cancer will be diagnosed in approximately 14,500
women. In this same year, about 4,800 women will die of cervical
cancer. The mortality rate from cervical cancer is more than twice as
high for black women as for white women.
The primary goal of cervical cancer screening is to increase
detection and treatment of precancerous cervical lesions and thus
prevent the occurrence
[[Page 36530]]
of cervical cancer. Although no clinical trials have studied the
efficacy of Papanicolaou (Pap) test in reducing cervical cancer
mortality, experts agree that it is an effective technology. Since the
introduction of the Pap test in the 1940s, cervical cancer mortality
rates have decreased by 75 percent. The rate of invasive cervical
cancer has decreased steadily over the last several decades and has
decreased approximately 2 percent each year since 1988. This decrease
is attributed to widespread use of the Pap test. Cervical carcinoma in
situ, a precancerous condition, is now more frequent than invasive
cancer, particularly among women younger than 50 years.
In 1991, the PHS established that by the year 2000, 85 percent of
women aged 18 years and older should be receiving a Pap test within the
preceding one to three years. Baseline data on the use of the Pap test
from the 1987 National Health Interview Survey (NHIS) show that only 75
percent of women aged 18 years and older reported having had a Pap test
within the past three years. Women who are minorities, are beyond their
reproductive years, have less education, and have a low income are less
likely to have had a recent Pap test.
Colorectal Cancer
Colorectal cancer is a major cause of morbidity and mortality. The
ACS estimates that in 1997, 131,200 people will be diagnosed with
colorectal cancer and that an estimated 54,900 people will die of this
cancer in the United States. When colorectal cancers are detected
early, the 5-year survival rate is 91 percent. For individuals who are
diagnosed with cancer that has spread regionally to involve adjacent
organs or lymph nodes, the rate drops to 63 percent.
The natural history of colorectal cancer makes it a disease
suitable for screening. Most colorectal cancers are thought to develop
over a period of many years from premalignant polyps, or adenomas.
Screening tests are available that can detect both preclinical adenomas
and early stage cancers. Thus, like cervical cancer, colorectal cancer
can, optimally, be prevented by the removal of premalignant lesions,
and survival is greatly enhanced when colorectal cancer is treated at
an early stage. Although the U.S. Preventive Services Task Force
currently recommends that clinicians screen for colorectal cancer with
periodic flexible sigmoidoscopy and annual fecal occult blood testing
(FOBT) for all persons aged 50 years and older, actual usage rates of
these screening tests are quite low. An estimated one-third of the
deaths from colorectal cancer could be prevented through screening.
Skin Cancer
Skin cancer is the most common and most rapidly increasing form of
cancer in the United States. Almost one million cases of skin cancer
are estimated to occur each year. The two major types of skin cancers
are nonmelanoma, which includes basal cell and squamous cell carcinoma,
and melanoma. Every decade, the incidence of melanoma doubles.
Mortality rates are also increasing. In the United States, the lifetime
risk of developing cutaneous malignant melanoma is currently 1 in 87.
If current trends continue, by the year 2000, the lifetime risk will
climb to 1 in 75. It is estimated that about 40,300 new cases of
melanoma will be diagnosed in 1997. Although nonmelanoma skin cancers
occur more frequently, about three quarters of skin cancer deaths are
attributed to malignant melanoma. In 1997, skin cancers of all kinds
will claim the lives of approximately 9,490 people'7,300 of malignant
melanoma and 2,190 of other skin cancers.
If detected and treated early, basal cell carcinoma has a cure rate
greater than 95 percent. Squamous cell carcinoma is also highly curable
if detected and treated early. Non-melanoma skin cancers can lead to
substantial morbidity, but mortality rates are low. Melanoma can be
treated successfully if detected early but can result in death if left
untreated. A person who has had one type of melanoma is at increased
risk of getting another type by five to nine times.
Since 1994, CDC has continued to develop partnerships and conduct
activities that have supported the growth of CDC's National Skin Cancer
Prevention Education Program. The program's aim is to increase public
awareness about skin cancer and to help the nation achieve skin cancer
prevention objectives established by Healthy People 2000. Currently
there is no scientific evidence to support mass screening for skin
cancer. Skin self examination, although not scientifically proven as
effective, is prudent for persons at high risk. The incidence and
mortality of skin cancer can be reduced by changing risk factors
associated with sun exposure. Educational programs for both adults and
children are important.
Purpose
These awards will assist private and public nonprofit national
organizations to educate their constituents about cancer prevention and
early detection issues; increase access to cancer screening programs;
to identify priority populations; and develop strategies for reaching
identified priority populations nationwide. Program options may include
generating publications; collaborating with State and local health
departments to implement model educational interventions; developing
technical assistance and training tools; developing, testing, and
evaluating cancer control efforts; and adopting cancer early detection
and control objectives as part of the national organization's
priorities.
Program Requirements
In conducting activities to achieve the purpose of this program,
the recipient will be responsible for the activities under A.
(Recipient Activities), and CDC will be responsible for conducting
activities under B. (CDC Activities).
A. Recipient Activities
1. Develop, evaluate, and disseminate programs or strategies
designed to improve cancer prevention, early detection, and control
among the priority population.
2. Develop and carry out educational strategies to improve
knowledge, attitudes, skills and behaviors regarding cancer prevention,
early detection, and control practices among the priority populations.
3. Establish specific, measurable, and realistic program objectives
at national, State, and local levels for the accomplishment of program
activities.
4. Identify and select appropriate staff.
5. Establish partnerships with CDC-funded State health departments,
American Indian/Alaska Native organizations, U.S. territories, and the
District of Columbia in implementing outreach programs and or
professional education.
6. Participate in a minimum of two meetings per year to facilitate
the accomplishment of program objectives.
7. Evaluate achievement through a well-designed evaluation plan
that assesses each objective component of the program.
8. Disseminate intervention information at the national, State, and
local levels regarding program achievements and activities.
9. Participate in the dissemination and sharing of pertinent
program information with other CDC funded grantees, appropriate
agencies and partners.
B. CDC Activities
1. Provide technical assistance.
2. Collaborate with recipients in the development, implementation,
[[Page 36531]]
evaluation, and dissemination of programs designed to improve the
knowledge, attitude, prevention, and screening behaviors of priority
populations and or the health care providers who serve them.
3. Provide periodic updates about public knowledge, attitudes, and
practices regarding prevention, early detection and control of cancer,
and up-to-date scientific information.
4. Collaborate with recipients to develop meeting agendas and
convene personnel from all recipient organizations and funded State and
territorial health departments, American Indian/Alaska Native tribes
and tribal organizations, and the District of Columbia for regular
meetings to review program activities.
5. Collaborate with recipients in the development of publications,
manuals, modules, etc. that relate to this award.
6. Facilitate the exchange of program information and technical
assistance and the development of partnerships between recipients
funded under this announcement, community organizations, health
departments, and other partners.
Technical Reporting Requirements
An original and two copies of a semiannual progress report are due
30 days after the end of the first six months and 30 days after the end
of the budget period. The progress reports must include the following
for each program, function, or activity involved: (1) a comparison of
actual accomplishments to the goals established for the period; (2) the
reasons for slippage if established goals were not met; and (3) other
pertinent information including, when appropriate, analysis and
explanation of unexpectedly high costs for performance.
An original and two copies of the financial status reports (FSR)
must be submitted no later than 90 days after the end of each budget
period. A final financial status and performance report are required no
later than 90 days after the end of the project period. All reports are
submitted to the Grants Management Branch, Procurement and Grants
Office, CDC.
Application Content
Applicants should focus on affecting the priority population that
they have the greatest likelihood of impacting. Interventions may be
targeted toward the priority population, health care providers, or
others who may impact cancer prevention and control services in the
priority populations. Priority populations are defined as uninsured,
underinsured, children and youths, older persons, racial and ethnic
minorities, those who live in hard-to-reach rural or urban communities,
and organizations that can impact the health of these populations.
Program definitions and information that can be helpful in
completing this application are attached.
Applicants must develop their applications in accordance with PHS
Form 5161-1 (Rev. 7-92, OMB Number 0937-0189), information contained in
the program announcement, and the instructions below. The application
including appendixes should be limited to no more than 50 single-spaced
pages, including PHS forms, budget information, and appendixes.
A. Background and Need
1. Describe the priority population as it relates to the purpose of
this program announcement, magnitude and scope of the problem within
the priority population, barriers to or gaps in cancer prevention and
control efforts, and proposed solutions to barriers or gaps.
2. Describe the organization's past and present program activities
in the prevention, early detection and control of cancers, especially
cancers of the breast, cervix, colon, rectum, and skin.
3. Describe the applicant's history and experience with and any
services provided to the priority population, and the rationale for use
of previously conducted or newly developed innovative strategies to
enhance the delivery of health messages, services, and or programs
regarding the prevention, early detection, and control of cancers,
especially cancers of the breast, cervix, colon, rectum, and skin.
B. Goals and Objectives
1. Objectives: Identify specific and time-related, measurable
objectives consistent with the purpose of the cooperative agreement.
2. Activities: Clearly identify the specific activities and
outreach strategies that will be undertaken to achieve each of the
program's objectives during the budget period.
3. Milestone Chart: Submit a milestone-to-completion chart
consistent with the time frame of the project period.
C. Capabilities
1. Describe nature and extent of constituent support for past and
present organizational activities related to screening and follow-up
for cancers, especially cancers of the breast, cervix, colon, rectum,
and skin.
2. Describe the nature and extent of health education activities,
especially those related to cancer screening and follow-up.
3. Provide a comprehensive plan for national dissemination of
program activities.
D. Project Management
1. Submit a copy of the organization's mission statement.
2. Describe the organization's structure and function, size,
national membership, substructure, activities on a regional, State, or
local level, and methods of routine communication with members
(newsletters journals, meetings, etc.).
3. Describe each current or proposed position for this program by
job title, function, general duties, and activities with which that
position will be involved. Include the level of effort and allocation
of time for each project activity by staff position. Minimal staffing
should include a full-time project coordinator.
E. Collaborative Activities
Describe past and proposed collaborative working partnerships with
providers, community groups who serve the priority population and or
have established linkages in the priority population. Include evidence
of collaborations with partners such as memorandums of agreement.
F. Program Evaluation Plan
Identify methods for measuring progress toward attaining program
objectives and monitoring activities. The evaluation plan should
include qualitative and quantitative data collection and assessment
mechanisms. This plan should include baseline data or the mechanism
that will be used to establish the baseline data; the outcomes to be
expected; the minimum data to be collected; the systems for collecting
and analyzing the data. Minimum data to be reported include, but are
not limited to the following:
1. Describe the number of persons in the priority population, the
number you expect to reach, and the plan for evaluating the number
actually reached.
2. Demographic information such as race, ethnicity, residence,
insurance status, annual income, etc.
3. Information about the health providers reached, such as
profession, worksite description, and populations served.
4. When, where, and how often activities are conducted.
G. Budget and Narrative Justification
Provide a detailed line-item budget and narrative justification of
all operating expenses consistent with the
[[Page 36532]]
proposed objectives and planned activities. Be precise about the
program purpose of each budget item and itemize calculations when
appropriate.
Applicants should budget for the following costs:
Out-of-State Travel: Participation in CDC-sponsored training
workshops and meetings is essential to the effective implementation of
cancer control programs. Travel funds should be budgeted for the
following meetings:
Three persons to Atlanta, Georgia to attend the Annual
National Cancer Prevention and Control Conference (3 days).
Three to five persons to Atlanta, Georgia to report
program implementation progress (reverse site visit) and for
consultation and technical assistance (2 days) (1 trip per year).
Up to 2 additional 2-person trips to Atlanta, or other
specified destination to attend or assist with national training center
educational programs on national work groups, task forces or committees
(1-3 days).
H. Attachments
Provide these attachments:
1. An organizational chart and resumes of current and proposed
staff.
2. A list of applicant's constituents by regional, State, and local
organization(s).
3. Evidence of collaboration with other organizations that serve
the same priority populations. Include Memorandums of Agreement and
letters of support.
4. A description of funding from other sources to conduct similar
activities:
(a) Describe how funds requested under this announcement will be
used differently or in ways that will expand on the funds already
received, applied for, or being received.
(b) Identify proposed personnel devoted to this project who are
supported by other funding sources and the activities they are
supporting.
(c) Ensure that the funds being requested will not duplicate or
supplant funds received from any other sources.
Typing and Mailing
Applicants are required to submit an original and two copies of the
application. Number all pages clearly and sequentially and include a
complete index to the application and its appendixes. The original and
each copy of the application must be submitted unstapled and unbound.
Print all material, single-spaced, in a 12-point or larger font on 8
\1/2\'' by 11'' paper, with at least 1'' margins and printed on one
side only.
Evaluation Criteria (100 Points)
The application will be reviewed and evaluated according to the
following criteria:
A. Background and Need (25 Points)
1. The extent to which the applicant demonstrates an understanding
of the program purpose and objectives (13 points).
2. The extent to which the applicant identifies the priority
population(s) and evidenced need for the proposed activities (12
points).
B. Goals and Objectives (20 Points)
The degree to which specific, time-related, and measurable
objectives and process and outcome measures are consistent with the
stated purposes of the cooperative agreement.
C. Capabilities (20 Points)
The quality and feasibility of the proposed program activities for
achieving the objectives. The extent to which applicants demonstrate
the ability to impact a segment of the priority populations (e.g.,
uninsured, underinsured, children and youths, older persons, racial and
ethnic minorities, and persons who live in hard-to-reach communities in
rural and urban America, etc.) for the cancer(s) they propose to
address. This ability may be demonstrated by providing documentation of
populations currently served, services provided, and linkages with
other health agencies and organizations, as well as by outlining a
cancer prevention and control plan consistent with generally accepted
theories and practices of public health.
D. Project Management (10 Points)
The adequacy of proposed personnel time allocations and the extent
to which proposed staff exhibit appropriate qualifications and
experience to accomplish the program activities.
E. Collaborative Activities (15 Points)
The appropriateness and relevance of collaborative linkages, and
the extent to which the applicant demonstrates the ability to access
the priority population(s) on a national basis and to disseminate
programs nationally.
F. Program Evaluation Plan (10 Points)
The quality of the evaluation plan for monitoring progress that
relates to intervention activities and objectives.
G. Budget and Justification (Not Weighted)
The extent to which the budget is reasonable and consistent with
the purpose and objectives of the cooperative agreement.
H. Human Subjects (Not Weighted)
Whether or not exempt from the DHHS regulations, procedures must be
adequate for the protection of human subjects. Recommendations on the
adequacy of protections include: (1) protections appear adequate and
there are no comments to make or concerns to raise, (2) protections
appear adequate, but there are comments regarding the protocol, (3)
protections appear inadequate and the Objective Review Group has
concerns related to human subjects, or (4) disapproval of the
application is recommended because the research risks are sufficiently
serious and protection against the risks are inadequate as to make the
entire application unacceptable.
Content of Noncompeting Continuation Applications
In compliance with 45 CFR 74.51(d), non-competing continuation
applications submitted within the project period need only include:
A. A brief progress report that describes the accomplishments of
the previous budget period.
B. Any new or significantly revised items or information
(objectives, scope of activities, operational methods, evaluation,
etc.) not included in the year 01 application.
C. An annual budget and justification. Existing budget items that
are unchanged from the previous budget period do not need
rejustification. Simply list the items in the budget and indicate that
they are continuation items. Supporting justification should be
provided where appropriate.
Executive Order 12372 Review
Applications are not subject to Executive Order 12372,
Intergovernmental Review of Federal Programs.
Public Health System Reporting Requirements
This program is not subject to the Public Health System Reporting
Requirements.
Catalog of Federal Domestic Assistance Number
The Catalog of Federal Domestic Assistance number is 93.283.
Other Requirements
Paperwork Reduction Act
Projects that involve the collection of information from 10
individuals or more and funded by the cooperative agreement will be
subject to review by
[[Page 36533]]
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act.
Application Submission and Deadline
The original and two copies of the application PHS Form 5161-1
(Revised 7-92, OMB Number 0937-0189) must be submitted to Sharron P.
Orum, Grants Management Officer, Procurement and Grants Office, Centers
for Disease Control and Prevention, 255 East Paces Ferry Road, NE.,
Room 300, Mail Stop E-15, Atlanta, GA 30305, on or before August 8,
1997.
1. Deadline: Applications shall be considered as meeting the
deadline if they are either:
(a) Received on or before the deadline date; or
(b) Sent on or before the deadline date and received in time for
submission to the objective review group. (Applicants must request a
legibly dated U.S. Postal Service postmark or obtain a legibly dated
receipt from a commercial carrier or U.S. Postal Service. Private
metered postmarks will not be accepted as proof of timely mailing.)
2. Late Applications: Applications that do not meet the criteria in
1.(a) or 1.(b) above are considered late applications. Late
applications will not be considered in the current competition and will
be returned to the applicant.
Where to Obtain Additional Information
A complete program description and information on application
procedures may be obtained in an application package. Business
management technical assistance may be obtained from Nealean K. Austin,
Grants Management Specialist, Grants Management Branch, Procurement and
Grants Office, Centers for Disease Control and Prevention (CDC), 255
East Paces Ferry Road, NE., Room 314, Mail Stop E-18, Atlanta, GA
30305; telephone (404) 842-6508 or the Internet at, nea1@cdc.gov.
Programmatic technical assistance may be obtained from Heidi Holt,
Division of Cancer Prevention and Control, National Center for Chronic
Disease Prevention and Health Promotion, Centers for Disease Control
and Prevention (CDC), 4770 Buford Highway NE., Mail Stop K-64, Atlanta,
GA 30341-3724; (770) 488-3085, or the Internet at: hym3@cdc.gov.
You may also obtain this announcement, and other CDC announcements,
from one of two Internet sites on the actual publication date: CDC's
homepage at http://www.cdc.gov or the Government Printing Office
homepage (including free on-line access to the Federal Register at
http://www.access.gpo.gov).
Please refer to Announcement number 773 when requesting information
and submitting an application.
Potential applicants may obtain a copy of Healthy People 2000 (Full
Report; stock No. 017-001-00474-0) or Healthy People 2000 (Summary
Report; stock No. 017-001-00473-1) referenced in the Introduction
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325; telephone (202) 512-1800.
Dated: July 1, 1997.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for
Disease Control and Prevention (CDC).
[FR Doc. 97-17699 Filed 7-7-97; 8:45 am]
BILLING CODE 4163-18-P
